NGM and Janssen strike diabetes agreement
This article was originally published in Scrip
Executive Summary
NGM Biopharmaceuticals, which develops treatments for cardio-metabolic diseases, has signed a worldwide agreement with Johnson & Johnson subsidiary, Janssen, to develop novel therapeutics for treating Type 2 diabetes and metabolic diseases.